scholarly journals Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations

2017 ◽  
Vol 117 (11) ◽  
pp. 1685-1688 ◽  
Author(s):  
Carlo Visco ◽  
Jinfen Wang ◽  
Maria Chiara Tisi ◽  
Lijuan Deng ◽  
Emanuele S G D'Amore ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
B Cell ◽  
B Cell Lymphomas ◽  
Molecular Features ◽  
Large B Cell

scholarly journals DIRECT-ACTING ANTIVIRALS DURING OR AFTER IMMUNO-CHEMOTHERAPY IN HEPATITIS C VIRUS-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS

2017 ◽  
Vol 35 ◽  
pp. 194-196
Author(s):  
M. Merli ◽  
L. Alric ◽  
L. Mannelli ◽  
F. De Angelis ◽  
A. Ferrari ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
B Cell ◽  
Direct Acting Antivirals ◽  
B Cell Lymphomas ◽  
Direct Acting ◽  
Large B Cell

scholarly journals Direct‐Acting Antivirals in Hepatitis C Virus‐Associated Diffuse Large B‐cell Lymphomas

2018 ◽  
Vol 24 (8) ◽  
Author(s):  
Michele Merli ◽  
Marco Frigeni ◽  
Laurent Alric ◽  
Carlo Visco ◽  
Caroline Besson ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
B Cell ◽  
Direct Acting Antivirals ◽  
B Cell Lymphomas ◽  
Direct Acting ◽  
Large B Cell

Direct-acting antivirals during or after immunochemotherapy in hepatitis C virus-positive diffuse large B-cell lymphomas

Hepatology ◽  
2017 ◽  
Vol 66 (4) ◽  
pp. 1341-1343 ◽  
Author(s):  
Michele Merli ◽  
Marco Frigeni ◽  
Manuel Gotti ◽  
Paolo Grossi ◽  
Raffaele Bruno ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
B Cell ◽  
Direct Acting Antivirals ◽  
B Cell Lymphomas ◽  
Direct Acting ◽  
Large B Cell

Hepatitis C virus‐associated indolent B‐cell lymphomas: A review on the role of the new direct antiviral agents therapy

2021 ◽  
Author(s):  
Cesare Mazzaro ◽  
Luigino Dal Maso ◽  
Marcella Visentini ◽  
Anna Ermacora ◽  
Pietro Andreone ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
B Cell ◽  
Antiviral Agents ◽  
B Cell Lymphomas ◽  
Direct Antiviral Agents

Primary hepatic or splenic diffuse large B-cell lymphoma and hepatitis C virus infection: a non-fortuitous association?

2000 ◽  
Vol 79 (9) ◽  
pp. 530-532 ◽  
Author(s):  
I. Genvresse ◽  
E. Späth-Schwalbe ◽  
H. Meisel ◽  
O. Kaufmann ◽  
D. H. Krüger ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Hepatitis C Virus Infection ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Concomitant Treatment of Hepatitis C Virus and Diffuse Large B-Cell Lymphoma with Direct-Acting Antivirals in HIV Coinfection: A Case Report

2019 ◽  
Vol 18 ◽  
pp. 232595821882206
Author(s):  
Alyssa Gallipani ◽  
Agnes Cha ◽  
Leonard Berkowitz ◽  
Anjali Bakshi
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Concomitant Treatment ◽  
Direct Acting Antivirals ◽  
Large B Cell Lymphoma ◽  
Direct Acting ◽  
Large B Cell

This report describes a case of concomitant treatment of advanced diffuse large B-cell lymphoma with chemoimmunotherapy along with direct-acting antivirals for hepatitis C virus in a patient coinfected with HIV. The patient tolerated gemcitabine, dexamethasone, cisplatin, and rituximab and achieved sustained virologic response after treatment with ledipasvir/sofosbuvir.

scholarly journals Convergent antibody responses associated with broad neutralization of hepatitis C virus and clearance of infection

2021 ◽  
Author(s):  
Nicole E. Skinner ◽  
Clinton O. Ogega ◽  
Nicole Frumento ◽  
Kaitlyn E. Clark ◽  
Srinivasan Yegnasubramanian ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
B Cell ◽  
Early Development ◽  
Neutralizing Antibodies ◽  
Vaccine Development ◽  
High Plasma ◽  
Spontaneous Clearance ◽  
Cell Repertoire ◽  
Molecular Features

AbstractEarly development of broadly neutralizing antibodies (bNAbs) targeting the hepatitis C virus (HCV) envelope glycoprotein E2 is associated with spontaneous clearance of infection, so induction of bNAbs is a major goal of HCV vaccine development. However, much remains to be learned at a molecular level about protective E2-reactive antibodies, since HCV infection persists in some individuals despite early development of broadly neutralizing plasma. To examine B cell repertoire features associated with broad neutralization and viral clearance, we performed RNA sequencing of the B cell receptors (BCRs) of HCV E2-reactive B cells of people with cleared or persistent HCV, including subjects with high or low plasma neutralizing breadth in both clearance and persistence groups. We identified many E2-reactive public BCR clonotypes, which are antibody clones with the same V and J-genes and identical CDR3 sequences, shared among subjects grouped by either clearance or neutralization status. The majority (89) of these public clonotypes were shared by two subjects with broad plasma neutralizing activity and cleared infection, but not found in subjects with high plasma neutralizing breadth and persistent infection. We cloned a potent, cross-reactive neutralizing monoclonal antibody (mAb) by pairing the most abundant public heavy and light chains from these two subjects, providing evidence that broadly E2-reactive public clonotypes arise in a subset of individuals with broadly neutralizing plasma and spontaneous clearance of infection. Further characterization of the molecular features and function of these antibodies can inform HCV vaccine development.

Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma

2020 ◽  
Vol 61 (9) ◽  
pp. 2122-2128 ◽  
Author(s):  
Michele Merli ◽  
Irene Defrancesco ◽  
Carlo Visco ◽  
Caroline Besson ◽  
Alice Di Rocco ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Direct Acting Antivirals ◽  
Large B Cell Lymphoma ◽  
Direct Acting ◽  
Large B Cell
Sign in / Sign up

Export Citation Format

Share Document